Venous thromboembolism and cancer: Prevention and therapy

Vnitrni Lekarstvi

Volumn 52, Issue SUPPL. 1, 2006, Pages 127-131

  Lee, Agnes Y Y ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cancer; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FLUOROURACIL; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; POSTOPERATIVE THROMBOSIS; REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33645462878     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997; 84: 1099-1103.
2. Mismetti P, Laporte S, Darmon JY et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913-930.
3. Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
4. Rasmussen MS, Wille-Jorgensen P, Jorgensen LN et al. Prolonged thromboprophylaxsi with low molecular weight heparin (dalteparin) following major abdominial surgery for malignancy. Blood 2003; 102: 56a (abstract 186).
5. Agnelli G, Bergqvist D, Cohen AT et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212-1220.
6. Couban S, Goodyear M, Burnell M et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063-4069.
7. Young AM, Begum G, Billingham LJ et al. WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheter (CVCs). Proc ASCO 2005; late breaking abstract 8004.
8. Masci G, Magagnoli M, Zucali PA et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003; 21: 736-739.
9. Karthaus M, Kretzschmar A, Kroning H et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17: 289-296.
10. Verso M, Agnelli G, Bertoglio S et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-4062.
11. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: I17-I21.
12. van Dongen CJ, van den Belt AG, Prins MH et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; CD001100.
13. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
14. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
15. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
16. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
17. Lee AY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.